GlassScriptPhysician profile
Vigen Khojayan
NPI 1477723203
$17,645.79
in general payments reported to CMS, 2019-2025
55 companies · $2,366 in 2025
The $2,366 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,421 · 2020: $2,304 · 2021: $3,807 · 2022: $1,958 · 2023: $2,259 · 2024: $2,532 · 2025: $2,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,065 · Education: $90.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,065.28 |
| Education | $90.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,606.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,412.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,356.68 | 2019-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $1,250.00 | 2021 | |
| Amgen INC. | $1,225.35 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,086.85 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $949.90 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $661.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $568.00 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $536.88 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $516.64 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $511.95 | 2021-2025 | |
| Ardelyx, INC. | $481.09 | 2024-2025 | Ibsrela |
| Allergan, INC. | $383.55 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $358.92 | 2023-2025 | Gemtesa |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vigen Khojayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.